Navigation Links
Promising Data ATIR Studies Presented by NIH Investigators
Date:11/28/2007

AMSTERDAM, November 28 /PRNewswire/ -- Kiadis Pharma announced today the presentation of the results obtained so far in the physician initiated study led by Dr. Stephan Mielke* and Dr. John Barrett* of the National Heart, Lung, and Blood Institute (NHLBI) a department of the National Institutes of Health (NIH) on Kiadis' lead product ATIR at the AABB annual meeting & TXPO 2007 in Anaheim, California.

According to the NHLBI investigators the challenge in the field of allogeneic bone marrow transplantations lies with disease control, Graft versus Host Disease (GvHD) control and donor availability. Doctors Barrett and Mielke have focused on controlling GvHD whilst sparing the Graft versus Leukemia (GvL) effect and also on increasing donor availability.

The investigators have published the preclinical data showing promising results with Kiadis Pharma's ATIR in eliminating alloreactive T cells from donor grafts (Mielke et al. Blood, 2007). These results have led to the start of a phase II study with ATIR by the NHLBI. This trial is designed to demonstrate that ATIR treatment may overcome the need of immunosuppressant prophylaxis post transplantation. Prophylaxis is currently standard practice to prevent GvHD, but has a serious drawback, as it increases the chance of infection and also the relapse rate. Thus ATIR does not only intend to prevent GvHD, but could also reduce the rates of infection and relapse. Together, these complications account for approximately 70 % of allogeneic transplant related mortality.

For the complete press release go to http://www.kiadis.com/News

*Note

Dr John Barrett is Chief of the Allotransplant Section at National Heart, Lung, and Blood Institute (NHLBI) of National Institutes of Health (NIH) in Bethesda, MD, USA, where the trial is being performed. Dr Stephan Mielke, who initiated this study as principal investigator at NHLBI, is currently working at the Julius-Maximilians University of Wurzburg, Germany and continues as the lead associate investigator on the protocol.

English release is provided by Kiadis Pharma. Equivalent translations are from a third party.


'/>"/>
SOURCE Kiadis Pharma
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
2. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
3. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
4. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
5. Argonne researcher studies what makes quantum dots blink
6. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
7. AIM-Quoted Verona Pharma Progresses Anti-Asthma Drug Studies
8. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
9. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
10. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
11. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Spain , Dec. 8, 2016  Anaconda BioMed ... the development of the next generation neuro-thrombectomy system for ... appointment of Tudor G. Jovin, MD to join its ... serve as a strategic network of scientific and clinical ... the development of the ANCD BRAIN ® to ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... launch of flexible packaging for their exceptionally efficient human mesenchymal stem/stromal cell ... RoosterBio’s portfolio of bioprocess media products engineered to radically streamline culture processes, ...
(Date:12/8/2016)... , ... December 08, 2016 , ... This CAST literature ... for biotech crops. The authors focus on the economic effects in countries that are ... of new biotech crops and the resultant risk of low level presence (LLP) puts ...
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. ... company focused on developing and commercializing products to treat ... announced today that it will be hosting an Investor ... ET on the origins of innate defense regulators (IDRs) ... review of oral mucositis and the recently announced and ...
Breaking Biology Technology:
(Date:11/17/2016)... CITY OF INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it ... about using NVMe storage servers in organizations that require high-performance scale-out plus high speed data transfer ... ... ... Setting ...
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:11/14/2016)... SARASOTA, Fla., Nov. 14, 2016  xG Technology, Inc. ... in providing critical wireless communications for use in challenging ... ended September 30, 2016. Management will hold a conference ... at 5:00 p.m. Eastern Time (details below). ... announced a $16 million binding agreement to acquire Vislink ...
Breaking Biology News(10 mins):